Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
RetinalGenix Technologies Inc. (RTGN)
Apollo Beach, CA, US
RetinalGenix Technologies Inc. is a company dedicated to research and development within the field of ophthalmology. Its core mission involves devising advanced technologies aimed at detecting, supervising, identifying, and treating a range of visual conditions, including those affecting the eyes and those that could lead to vision loss. Their product lineup features the RetinalGeniX Imaging System, an apparatus for broad-scale retinal imaging and screening that does not require pupil dilation, particularly useful for diabetic patients. Additionally, they offer the RetinalCam, a device designed for real-time retinal monitoring and imaging in a home setting, which includes an alert function for medical practitioners. The company was founded in 2017, with its principal offices located in Petaluma, California. RetinalGenix Technologies Inc. operates as a subsidiary of Sanovas Ophthalmology, LLC.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +25.00% | +25.00% | +25.00% | +25.00% | +9.59% | -55.56% | +33.33% | +33.33% | -44.83% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Devices: +11.2%—
-
EPS growth Medical - Devices: +28.5%+45.8% ★ Q1'26: +5.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%—
-
EBIT margin Medical - Devices: +6.2%—
-
ROIC Medical - Devices: +3.3%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+3.5% Q1'26: +1.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×—
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2015-04-30 | Conley Richard K | Director | A-Award | A | Stock option (right to buy) | 5,000 | 3.35 | 16.8K | 5,000 | — | ↗ |
| 2015-04-30 | Akao Akihisa | Director | A-Award | A | Stock option (right to buy) | 5,000 | 3.35 | 16.8K | 5,000 | — | ↗ |
| 2015-03-23 | Oculus Innovative Sciences, Inc. | 10% Owner | S-Sale | D | Common Stock, $0.0001 par value per share | 350,000 | 2.75 | 962.5K | 1,650,000 | — | ↗ |
| 2015-02-27 | Akao Akihisa | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-05-12 | Conley Richard K | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 6.37 | 63.7K | 10,000 | — | ↗ |
| 2014-05-11 | Conley Richard K | Director | A-Award | A | Common Stock | 58,000 | 0.00 | — | 58,000 | — | ↗ |
| 2014-03-26 | Oculus Innovative Sciences, Inc. | 10% Owner | — | D | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 2,000,000 | — | ↗ |
| 2014-03-21 | Conley Richard K | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jerry Katzman | Chief Executive Officer, President, Interim Chief Financial Officer & Chairman | 661.5K | — |
| Cory Zwerling | CFO & Interim COO | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RTGN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
